Smith Group Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-70
| Closed | -$7K | – | 389 |
|
|
2021
Q2 | $7K | Hold |
70
| – | – | ﹤0.01% | 333 |
|
|
2021
Q1 | $8K | Sell |
70
-1,890
| -96% | -$216K | ﹤0.01% | 284 |
|
|
2020
Q4 | $271K | Hold |
1,960
| – | – | 0.02% | 165 |
|
|
2020
Q3 | $161K | Sell |
1,960
-10
| -0.5% | -$821 | 0.01% | 178 |
|
|
2020
Q2 | $154K | Sell |
1,970
-30
| -2% | -$2.35K | 0.01% | 173 |
|
|
2020
Q1 | $89K | Hold |
2,000
| – | – | ﹤0.01% | 221 |
|
|
2019
Q4 | $85K | Hold |
2,000
| – | – | ﹤0.01% | 247 |
|
|
2019
Q3 | $86K | Buy |
2,000
+320
| +19% | +$13.8K | ﹤0.01% | 246 |
|
|
2019
Q2 | $107K | Buy |
1,680
+310
| +23% | +$19.7K | ﹤0.01% | 233 |
|
|
2019
Q1 | $95K | Sell |
1,370
-4,600
| -77% | -$319K | ﹤0.01% | 264 |
|
|
2018
Q4 | $260K | Sell |
5,970
-100
| -2% | -$4.36K | 0.01% | 223 |
|
|
2018
Q3 | $463K | Buy |
6,070
+1,420
| +31% | +$108K | 0.01% | 201 |
|
|
2018
Q2 | $357K | Hold |
4,650
| – | – | 0.01% | 207 |
|
|
2018
Q1 | $237K | Sell |
4,650
-3,900
| -46% | -$199K | 0.01% | 236 |
|
|
2017
Q4 | $397K | Hold |
8,550
| – | – | 0.01% | 219 |
|
|
2017
Q3 | $455K | Hold |
8,550
| – | – | 0.02% | 222 |
|
|
2017
Q2 | $531K | Sell |
8,550
-100
| -1% | -$6.21K | 0.02% | 210 |
|
|
2017
Q1 | $586K | Sell |
8,650
-10
| -0.1% | -$677 | 0.02% | 179 |
|
|
2016
Q4 | $609K | Sell |
8,660
-100
| -1% | -$7.03K | 0.02% | 179 |
|
|
2016
Q3 | $621K | Hold |
8,760
| – | – | 0.02% | 172 |
|
|
2016
Q2 | $428K | Sell |
8,760
-710
| -7% | -$34.7K | 0.01% | 190 |
|
|
2016
Q1 | $600K | Buy |
9,470
+1,840
| +24% | +$117K | 0.02% | 166 |
|
|
2015
Q4 | $856K | Buy |
+7,630
| New | +$856K | 0.03% | 180 |
|